Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4280 - Mechanism of Pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Colon and Rectal Cancer

Presenters

SANJAY GOEL

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

S. GOEL1, A. Ocean2, I. Chaudhary1, M.H. Ghalib1, E. Kaledzi1, U. Shah1, A.A. GUTIERREZ3, M. Coffey3, G. Gill3, R. Maitra1

Author affiliations

  • 1 Medical Oncology, Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, 10461 - Bronx/US
  • 2 Medical Oncology, NewYork-Presbyterian/Weill Cornell Medical Center, 10021 - New York/US
  • 3 Clinical Development, Oncolytics Biotech Inc, T2N 1X7 - Calgary,/CA
More

Resources

Abstract 4280

Background

Pelareorep (REOLYSIN) is an immuno oncology viral agent that contains a naturally occurring, ubiquitous, non-enveloped human dearing strain reovirus. Pelareorep selectively replicates in tumor cells harboring gene mutations that downregulate the IFN-induced antiviral response (e.g., KRAS-mutations) which results in their lysis. Pel is synergistic with irinotecan (IRI) in in vitro and in vivo models.

Methods

This is a phase I dose escalation study of FOLFIRI/B + Pel. Eligible pts are adults with oxaliplatin refractory KRAS-mutant mCRC. Both, IRI (150-180 mg/m2) and Pel (1x1010 TCID50 to 3x1010 TCID50) were escalated. Pel was given IV over 1 hr days 1-5 every 4 weeks (wk). Primary objectives were to determine toxicity, recommended phase two dose (RPTD), and pharmacokinetics. Secondary objectives were response rate, progression-free and overall survival (PFS and OS). Tumor biopsies post Pel were optional and subject to electron microscopy (EM).

Results

36 pts enrolled; FOLFIRI naïve (24) and pre-treated (12). Common (>10%) grade 3-4 toxicity include: neutropenia, anemia, and thrombocytopenia. At 180 mg/m2 of IRI, among FOLFIRI pretreated pts, 2 had dose-limiting toxicity (DLT) in cycle 1; in FOLFIRI naïve patients, none/6 had a DLT, with a median PFS of 49 wk (range: 10-91 wk). 5 patients are currently on therapy. The RPTD is IRI 180 mg/m2 and Pel 3x1010 TCID50. Of 32 evaluable pts, 3 had a partial response. EM of tumor biopsies showed dying cells with degenerating endoplasmic reticulum, large nonfunctional mitochondria, heterochromatin, condensed DNA, and viral factories, both empty and active. There were discrete holes in the cytoplasm leading to dampening of cellular proliferation. Immunogold staining against viral capsid protein σ demonstrated viral “homing” in the tumor cells. Flow cytometry reveals expansion of dendritic cells with consequent activation of cytotoxic T cells.

Conclusions

The combination was safe, well tolerated, with a PFS (49 wk), superior to historic data (25-30 wk). Detailed PK and immune data will be presented.

Clinical trial identification

NCT01274624

Legal entity responsible for the study

Oncolytics Inc.

Funding

Conquer Cancer Foundation

Disclosure

S. Goel: Research Funding from Oncolytics Inc. A. Ocean: Research Funding from Oncolytics Inc. A.A. Gutierrez: Chief Medical Officer of Oncolytics Biotech Inc. Employee of Oncolytics Biotech Inc. (or one of its affiliated corporations) and own shares in or have options to purchase shares in Oncolytics Biotech Inc. M. Coffey: President and CEO of Oncolytics Biotech Inc. Employee of Oncolytics Biotech Inc. (or one of its affiliated corporations) and own shares in or have options to purchase shares in Oncolytics Biotech Inc. G. Gill: Employee of Oncolytics Biotech Inc. (or one of its affiliated corporations) and own shares in or have options to purchase shares in Oncolytics Biotech Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.